Replies to post #15037 on Mymetics Corp (MYMX)

[bow-tie]

Bill & Melinda Gates Foundation Discovery Humabs BioMed Rabies mABs Infectious Diseases Rabies Infection Licensed to Indian Immunologicals Ltd. Humabs BioMed S. aureus mAb Bacterial Infection S. aureus Infection Exclusively licensed to MedImmune

https://www.swissbiotech.org/wp-content/uploads/2019/04/sba-members-pipeline-201802-web-1.pdf

MAb-114 is the lead from a series of lyophilized human IgG1 MAbs also targeting the Zaire ebolavirus glycoprotein. It was isolated and characterized in Switzerland at the Institute for Research in Biomedicine in collaboration with Humabs Biomed SA, a subsidiary of Vir Biotechnology Inc., of San Francisco.

[Work Harder]

Nice snag

The dIgA1 version could bind twice as many virus particles as the dIgA2 version. “That was a Eureka moment,” Ruprecht says, adding that the dIgA1 version can bind more virions because of its shape. Its antigen binding sites, which are located at the end of the arms of the “Y” of the antibody molecule, are further apart from each other than the antigen binding sites of dIgA2. As a result, dIgA1 can accommodate four viruses between its antigen binding sites, while dIgA2 can only accommodate two.

This also explains why dIgA1 fared best in another experiment: In contrast to dIgA2 and IgG1, only dIgA1 was able to keep most HIV particles from crossing a cultured epithelial cell layer in a so-called “transcytosis” assay, which simulates the crossing of HIV through the kind of epithelial cell layer found at mucosal surfaces.

These results suggest that vaccine developers should try to find vaccines that can coax the body’s immune system to produce mucosal HIV-specific dimeric and multimeric IgA1 antibodies, says Ruprecht. Such antibodies don’t necessarily have to be neutralizing, because it was dIgA1’s ability to bind more HIV particles—not to better neutralize the virus—that was responsible for the better protection by dIgA1 in the study.

“The very next question is, how can you best induce these types of protective mucosal responses?” says Ruprecht.

https://www.genengnews.com/topics/translational-medicine/vir-grows-with-500m-in-financing-humabs-acquisition-two-up-to-1b-collaborations/

Vir Grows with $500M in Financing, Humabs Acquisition, Two Up-to-$1B Collaborations

Vir has acquired Humabs BioMed, a Swiss discoverer and developer of fully human monoclonal antibodies to treat serious infections, for an undisclosed price.

Vir also announced agreements of undisclosed value with four academic research institutions:
Stanford University—Vir has licensed artificial intelligence technology designed to mine gene expression data for early diagnostic predictions and target discovery.
Harvard University—Under a five-year strategic research alliance, Vir agreed to foster scientific collaboration with Harvard and provide financial support for innovative research projects in infectious diseases, to which Vir will have exclusive access to negotiate licenses.
Oregon Health & Science University—Vir expanded an existing relationship with OHSU to include additional sponsored research. OHSU remains a key partner, Vir said, in the development of its cytomegalovirus (CMV) vaccine platform.
Fred Hutchinson Cancer Research Center—Vir and Fred Hutch have inked a sponsored research agreement focused on cell therapy.

[Work Harder]

SenzaGen and MB Research Labs sign toxicology agreement

https://www.manufacturingchemist.com/news/article_page/SenzaGen_and_MB_Research_Labs_sign_toxicology_agreement/152523

Animals will thank SenzaGen as it has signed a licence agreement with MB Research Labs, an animal-free, in vitro toxicological testing CRO in the US. The agreement gives MB Research Labs the right to market and sell immunotoxicity tester's GARDtest platform worldwide, simultaneously strengthening the Swiss company’s presence in the US market.

As a proponent of modern cell- and mechanistic-based solutions MB Research performs in vitro toxicological testing in the US, directed at cosmetic, consumer product and industrial chemical industries. This compliments SenzaGen’s focus on in vitro assays for immunotoxicity testing of chemicals.

Anki Malmborg Hager, CEO of SenzaGen, said: "By adding an additional CRO to our sales channels in the US, we have now given more end customers access to our innovative tests. In addition, with a driven and respected partner, we are increasing the possibilities of accelerating a change throughout the toxicological testing industry."

A keen interest in animal-free and alternative test methods is building, with introductions in legislation to ban animal testing for cosmetic and other products.

California was the first state to pass this type of legislation and the US animal-free market is expected to grow as more states follow suit. Even now, the US is an important market that currently accounts for just over one-third of the global market for cell-based in vitro testing.

SenzaGen's GARD product portfolio consists of a set of allergy tests. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence. This method is building in popularity to replace animal experiments for the cosmetics, chemical and pharmaceutical industries for their tests on whether chemical substances in products can be allergenic.

[Work Harder]

K. Anders O. Härfstrand, M.D., Ph.D.,

President and Chief Executive Officer of

Humabs BioMed SA (a biotechnology company) from 2011 to 2012

Dr. Henney was also a director of Mymetics Corporation during 2012.

http://ir.prothena.com/static-files/d1ccd3c3-b163-4901-a989-28b4a62fce1f

[Work Harder]

Look familiar

Antibody-mediated immune exclusion of HIV

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604883/

The role of mucosal anti-HIV IgA in humans is less well studied, although data from the Ugandan trial in uncircumcised men and high-risk Kenyan women linked mucosally produced neutralizing IgA to lower risks of HIV acquisition

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141757187

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152542295

Our working hypothesis is that mucus proteins as well as the epithelial tissue environment play key roles in this protection, the mechanism(s) of which need to be elucidated in future studies. The potent protection provided by the mucosally administered nmAbs give impetus to not only induce mucosal antiviral Ab responses of different classes by active immunization, but also to consider further development of topical nmAb prophylaxis in parallel. Lessons learned from the anti-HIV-1 studies will also be of significance for the development of strategies that seek to prevent mucosal transmission of other pathogens.